Ratings CureVac N.V.

Equities

CVAC

NL0015436031

Real-time Estimate Cboe BZX Other stock markets 03:20:36 2024-04-24 pm EDT			5-day change	1st Jan Change
2.405 ^USD	-7.50%		-5.84%	-42.52%

06:28pm	CureVac Begins Early Stage Portion of Investigational Vaccine Trial	MT
04:47pm	CureVac Hires New Chief Business Officer	MT

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation
According to Refinitiv, the company's ESG score for its industry is poor.

Strengths

Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
Over the past four months, analysts' average price target has been revised downwards significantly.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
CUREVAC N.V.	-42.52%	582M	D+
IQVIA HOLDINGS INC.	+3.74%	43.43B	B
LONZA GROUP AG	+47.81%	41.69B	A
MODERNA, INC.	+8.96%	41.31B	B-
CELLTRION, INC.	-10.92%	27.14B	C
ICON PUBLIC LIMITED COMPANY	+8.49%	25.28B	B-
ALNYLAM PHARMACEUTICALS, INC.	-24.90%	18.47B	B
MEDPACE HOLDINGS, INC.	+29.22%	12.59B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+0.83%	12.33B	C+
UNITED THERAPEUTICS CORPORATION	+8.81%	11.03B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes